UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APF	ROVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per respor	nse 0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																
Name and Address of Reporting Person * Chin Mark					2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.					3. Date of Earliest Transaction (Month/Day/Year) 10/30/2018								r (give title belo	ow)		(specify belo	w)	
DUBLIN, L2 2				4.	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City)	(State)	(Zip))	Table I - Non-Derivative Securities Acquired, Disposed of, or Benefi						Beneficial	lly Ow	ned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		y	zemed 3. Trans code (Instr. 8		2		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Beneficiall	t of Securities lly Owned Following Transaction(s) nd 4)		Form Direc	ership : Ber et (D) Ow	7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Сс	de	V	Amount	(A) or (D)	Price				(I)	` '	
Ordinary	Shares		10/30/201	8			I	9		58,000	A	\$ 6.1	1,089,903	3		I By Arix Bioscience Holdings Ltd. (1)		
Reminder: indirectly.	Report on a	separate line t	for each class	s of securiti	ies benefici	ally o	owned		Pers	ons wh	n this f	orm a	o the colle re not req	uired to re	spond u	ınless		1474 (9- 02)
			Tab		ivative Sec			•		•			ally Owned	l				
Security	Conversion	se (Month/Day/	(Day/Year) Execution any	Deemed ution Date,	4. if Transac Code ar) (Instr. 8	tion	5. Number on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. An Un Sec	Title and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	re de la	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)	
					Code		(A) (D)		Date Exe	-	Expirati Date	on Tit	Amount or Number of Shares	or Number of				
Renor	ting ()	wners																

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Chin Mark C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	X						

Signatures

/s/ Alan Hambelton, Attorney-in-Fact	11/01/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person is an Investment Director for Arix Bioscience Holdings Ltd.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see}\ Instruction\ 6 for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.